The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 study of fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) versus cemiplimab plus placebo in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) with positive PD-L1 expression.
 
Danny Rischin
Research Funding - ALX Oncology (Inst); AstraZeneca (Inst); Bicara Therapeutics (Inst); Decibel Therapeutics (Inst); Erasca, Inc (Inst); Merck (Inst); Regeneron (Inst)
(OPTIONAL) Uncompensated Relationships - Eisai; GlaxoSmithKline; Merck; Regeneron
 
Paolo Bossi
Honoraria - Angelini; BeiGene; Daiichi-Sankyo; Genmab/Seagen; GlaxoSmithKline; Merck; Merus; MSD Oncology; Pfizer; Regeneron; Sun Pharma
Consulting or Advisory Role - Angelini Pharma; Daiichi-Sankyo; Genmab/Seagen; GlaxoSmithKline; Merck Serono; MSD Oncology; Nutricia; Sanofi/Regeneron; Sun Pharma
Research Funding - BeiGene (Inst); GlaxoSmithKline (Inst); Merck Serono (Inst); MSD Oncology (Inst); Regeneron (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Merck Serono
 
Nabil Saba
Honoraria - Coherus Biosciences; EMD Serono; Exelixis; Fulgent Pharma; GlaxoSmithKline; Merck; Nanobiotix; Novartis; Surface Oncology; TOSK
Consulting or Advisory Role - Akeso Biopharma; Fulgent Pharma; Seagen
Research Funding - Bristol-Myers Squibb; Exelixis
Patents, Royalties, Other Intellectual Property - Springer textbook Royalty; Uptodate chapter writing and editing
Travel, Accommodations, Expenses - Merck
 
Tanguy Seiwert
Honoraria - Merck
Consulting or Advisory Role - Arcus Biosciences; AstraZeneca; Bayer; BioNTech SE; BostonGene; CUE Biopharma; Eisai; Exelixis; Innate Pharma; IO Biotech; ITeos Therapeutics; Merck; Nanobiotix; Regeneron; Sanofi; Seattle Genetics/Astellas; Surface Oncology; VIR Biotechnology
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cue Biopharma (Inst); Dracen (Inst); Genentech/Roche (Inst); Merck (Inst); Nanobiotix (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - BostonGene; Coherus Biosciences; Nanobiotix
 
Deborah Wong
Consulting or Advisory Role - Coherus Biosciences; Merck; RAPT Therapeutics
Research Funding - AstraZeneca/MedImmune (Inst); Bicara Therapeutics (Inst); BioNTech SE (Inst); Bristol-Myers Squibb (Inst); Elevar Therapeutics (Inst); Enzychem Lifesciences (Inst); Flamingo Pharma (Inst); FSTAR (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hookipa Biotech (Inst); invoX pharma (Inst); Lilly; Lilly (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Regeneron (Inst); Sensei Biotherapeutics (Inst); TopAlliance BioSciences Inc (Inst)
 
Qiong Zhao
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Shikha Bansal
No Relationships to Disclose
 
Mark Salvati
Employment - Amgen; Regeneron
Stock and Other Ownership Interests - Amgen; Regeneron
 
Israel Lowy
Employment - Regeneron
Leadership - Regeneron
Stock and Other Ownership Interests - Regeneron
Patents, Royalties, Other Intellectual Property - Regeneron
 
Matthew Fury
Employment - Regeneron; Regeneron (I)
Stock and Other Ownership Interests - Regeneron; Regeneron (I)
Research Funding - Regeneron
Patents, Royalties, Other Intellectual Property - Regeneorn; Regeneron (I)
 
Ahmed Khaled
Employment - Regeneron
Leadership - Regeneron
Research Funding - Regeneron
Patents, Royalties, Other Intellectual Property - Regeneron